ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Novartis Ag

Novartis Ag (0K9E)

76,79
0,00
(0,00%)
Fermé 03 Février 5:30PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
76,79
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
20 552
0,00 Fourchette du Jour 0,00
76,79 Plage de 52 semaines 76,79
Cap du marché
Clôture Veille
76,79
Ouverture
-
Dernière Transaction
70
@
104.6005
(O)
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
4 719
Actions en circulation
2 044 034 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
13,93
Bénéfice par action (BPA)
7,27
Chiffre d'affairess
54,11B
Bénéfice net
14,85B

À propos de Novartis Ag

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
Siège social
Basel, Che
Fondé
-
Novartis Ag est coté dans le secteur Pharmaceutical Preparations de la London Stock Exchange avec le ticker 0K9E. Le dernier cours de clôture d'Novartis était de US$76,79. Au cours de la dernière année, les actions de Novartis ont été négociées dans une fourchette de prix de US$ 76,79 à US$ 76,79.

Novartis compte actuellement 2 044 034 000 actions en circulation. La capitalisation boursière d'Novartis est de US$156,96 milliard. Novartis a un ratio cours/bénéfice (ratio PE) de 13.93.

0K9E Dernières nouvelles

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Strong Sales Growth, Margin Expansion And Breakthrough Innovation Launching Five...

N -- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): -- Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc...

NOVARTIS AG CHF0.50(REGD) Novartis Erzielt 2019 Ein Starkes Umsatzwachstum, Margen-steigerungen Und Bahnbrechende Innovatione...

N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): -- Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von...

NOVARTIS AG CHF0.50(REGD) Novartis A Réalisé En 2019 Une Forte Croissance De Son Chiffre D'affaires, Une Augmentation De Sa...

N -- Hausse du chiffre d'affaires net des activités poursuivies1 de 9% sur l'exercice entier (tcc2, +6% USD): -- Pharmaceuticals: cette unité opérationnelle progresse de...

NOVARTIS AG CHF0.50(REGD) Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Company

N Basel, January 6, 2020 -- Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned...

NOVARTIS AG CHF0.50(REGD) Novartis Provides Update On Luster Phase Iii Studies In Patients With Uncontrolled Gina 4/5 Asthma

N -- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -- Fevipiprant was well tolerated with adverse events balanced across...

NOVARTIS AG CHF0.50(REGD) Novartis Tender Offer For The Medicines Company Commences

N Basel, December 5, 2019 -- Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation...

NOVARTIS AG CHF0.50(REGD) Novartis To Acquire The Medicines Company For Usd 9.7 Bn, Adding Inclisiran, A Potentially Transfor...

N -- Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve...

NOVARTIS AG CHF0.50(REGD) New Novartis Medicine Adakveo(R) (crizanlizumab) Approved By Fda To Reduce Frequency Of Pain Crises...

N -- Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 -- Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to...

NOVARTIS AG CHF0.50(REGD) Novartis Cosentyx(R) Shows Encouraging Results Versus Humira(R)* From First-of-its-kind Head-to-hea...

N -- Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira(R)*[1]...

NOVARTIS AG CHF0.50(REGD) Novartis Announces Avxs-101 Intrathecal Study Update

N -- FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study -- Adverse events that might be expected from the...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10076.7976.7976.7941976.79DE
40076.7976.7976.791057676.79DE
120076.7976.7976.79471976.79DE
260076.7976.7976.79337176.79DE
520076.7976.7976.79960176.79DE
1560076.7976.7976.792144576.79DE
2600076.7976.7976.791788776.79DE

0K9E - Frequently Asked Questions (FAQ)

What is the current Novartis share price?
The current share price of Novartis is US$ 76,79
How many Novartis shares are in issue?
Novartis has 2 044 034 000 shares in issue
What is the market cap of Novartis?
The market capitalisation of Novartis is USD 156,96B
What is the 1 year trading range for Novartis share price?
Novartis has traded in the range of US$ 76,79 to US$ 76,79 during the past year
What is the PE ratio of Novartis?
The price to earnings ratio of Novartis is 13,93
What is the cash to sales ratio of Novartis?
The cash to sales ratio of Novartis is 3,83
What is the reporting currency for Novartis?
Novartis reports financial results in USD
What is the latest annual turnover for Novartis?
The latest annual turnover of Novartis is USD 54,11B
What is the latest annual profit for Novartis?
The latest annual profit of Novartis is USD 14,85B
What is the registered address of Novartis?
The registered address for Novartis is PO BOX, BASEL, 4002
What is the Novartis website address?
The website address for Novartis is www.novartis.com
Which industry sector does Novartis operate in?
Novartis operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
AIQAiq Limited
4,00p
(33,33%)
37,88k
INSPInspirit Energy Holdings Plc
0,0036p
(28,57%)
1,43B
ALKAlkemy Capital Investments Plc
175,00p
(27,27%)
176,27k
KNBKanabo Group Plc
1,00p
(25,00%)
461,04k
TCFTheracryf Plc
1,125p
(25,00%)
6,72M
MET1Metals One Plc
0,275p
(-35,29%)
16,2M
PPSProton Motor Power Systems Plc
0,175p
(-22,22%)
848,7k
SYMESupply@me Capital Plc
0,0025p
(-19,35%)
372,49M
CGNRConroy Gold & Natural Resources Plc
2,15p
(-18,87%)
739,53k
ONCOncimmune Holdings Plc
10,40p
(-16,47%)
1,19M
INSPInspirit Energy Holdings Plc
0,0036p
(28,57%)
1,43B
NTVONativo Resources Plc
0,0018p
(-5,26%)
1,41B
MSMNMosman Oil And Gas Limited
0,041p
(10,81%)
1,22B
TRPTower Resources Plc
0,0295p
(0,00%)
691,76M
SYMESupply@me Capital Plc
0,0025p
(-19,35%)
372,49M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock